Publication

Il-21 fusion proteins useful as enhancers of anti-cancer immunotherapies

Related publications (32)

Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells

Li Tang, Lixia Wei, Yuqing Xie, Hacer Arik

Interleukin-2 (IL-2) is a potent T-cell mitogen that can adjuvant anti-cancer adoptive T-cell transfer (ACT) immunotherapy by promoting T-cell engraftment. However, the clinical applications of IL-2 in combination with ACT are greatly hindered by the sever ...

2019

Immunoengineering with biomaterials for enhanced cancer immunotherapy

Li Tang, Lixia Wei, Yuqing Xie

Cancer immunotherapy has recently shown dramatic clinical success inducing durable response in patients of a wide variety of malignancies. Further improvement of the clinical outcome with immune related cancer treatment requests more exquisite manipulation ...

2018

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Michele De Palma, Céline Wyser Rmili, Ece Kadioglu, Nicolo Rigamonti, Damya Laoui, Antonino Cassarà

Pathological angiogenesis is a hallmark of cancer and a therapeutic target. Vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2; also known as ANG2) are proangiogenic cytokines that sustain tumor angiogenesis and limit antitumor immunit ...

American Association for the Advancement of Science2017

Targeting cancer stem cells by T cell engineering

Nicolas Pierre Desbaillets

The identification of cancer stem cells (CSCs) has fundamentally changed the understanding of tumor biology. CSCs drive tumor initiation and long term tumor growth, can cause relapse and are essential for metastatic colonization. These features place cance ...

EPFL2017

Engineering Lymphangiogenesis

Manuel Andreas Fankhauser

Melanoma causes the vast majority of skin cancer deaths, and there is currently no conventional treatment available that is able to cure metastatic melanoma patients. However, a novel treatment modality has recently emerged: cancer immunotherapy. Cancer im ...

EPFL2016

Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors

Anne Planche, Tania Santoro

Background: Blocking the mechanistic target of rapamycin complex-1 (mTORC1) with chemical inhibitors such as rapamycin has shown limited clinical efficacy in cancer. The tumor microenvironment is characterized by an acidic pH which interferes with cancer t ...

Biomed Central Ltd2016

In-Vivo Detection and Tracking of T Cells in Various Organs in a Melanoma Tumor Model by F-19-Fluorine MRS/MRI

Lothar Helm, Pascal Miéville, Hikari Ananda Infinity Yoshihara, Olivier Michielin

Background F-19-MRI and F-19-MRS can identify specific cell types after in-vitro or in-vivo F-19-labeling. Knowledge on the potential to track in-vitro F-19-labeled immune cells in tumor models by F-19-MRI/MRS is scarce. Aim To study F-19-based MR techniqu ...

Public Library of Science2016

6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice

Jeffrey Alan Hubbell, Melody Swartz, Laura Jeanbart, Iraklis Kourtis

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that suppress effector T cell responses and can reduce the efficacy of cancer immunotherapies. We previously showed that ultra-small polymer nanoparticles eff ...

Springer2015

Engineering opportunities in cancer immunotherapy

Melody Swartz, Laura Jeanbart

Immunotherapy has great potential to treat cancer and prevent future relapse by activating the immune system to recognize and kill cancer cells. A variety of strategies are continuing to evolve in the laboratory and in the clinic, including therapeutic non ...

Natl Acad Sciences2015

Targeting and Modulating Tumor-Associated Sites with Novel Nanoparticle-Based Immunotherapies

Laura Jeanbart

Cancer is a global disease and a leading cause of death worldwide. While surgery, radiotherapy and chemotherapy comprise the classical tools to eradicate tumors, they do not cure cancer, cannot prevent metastases, lead to side effects, and most importantly ...

EPFL2013

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.